May Livzon Bring The Reviving
Hope to The World

Frontier Standard Traceability
(WHO International Standard)
Excellent Performance

Evaluation solutions for
COVID-19 vaccines

PRODUCT OVERVIEW

The product can be used to evaluate the immune effect after vaccination or whether neutralizing antibodies are produced in human body after infection with 2019-nCoV.

PRODUCT APPLICATION

- Vaccine effectiveness evaluation
- Protective immunity indication
- Revaccination assessment
- Long-term protective immunity after recovery

KEY FAETURES

- **Clinical performance**

Compared with reference test by testing 125 positive and 147 negative specimens for SARS-CoV-2 neutralizing antibody.

Method		Reference Test		Total
		Positive	Negative	
2019-nCoV Neutralizing Antbodies Test (Fluorescence Immunochromatographic Assay)	Positive	123	1	124
	Negative	2	146	148
Total		125	147	272

Positive percent agreement: 123/(123+2)x100%=98.4%[95%CI:94.4%-99.6%]
Negative percent agreement: 146/(146+1)x100%=99.3%[95%CI:96.2%-99.9%]
Overall percent agreement: 123/(146+146)x100%=98.9%[95%CI:96.8%-99.6%]

- **Linearity**



- **Limit of detection※**

Not more than 5 IU/mL

※Traceability: First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136

ORDER INFORMATION

Product Name	Cat. No.	Shelf life	Specimen	Storage Conditions	Packaging
2019-nCoV Neutralizing Antibodies Test	G01802020	12 months	Serum/Plasma/ Venous whole blood	2~30°C	20 tests/kit